A new pathway for penicillin delabeling in Norway

Marie Bjørbak Alnæs, Oddvar Oppegaard, Bård Reiakvam Kittang, Stein Håkon Låstad Lygre, Anine Bernhoft Langeland, Brita Skodvin, Tormod Bjånes, Torgeir Storaas, Marie Bjørbak Alnæs, Oddvar Oppegaard, Bård Reiakvam Kittang, Stein Håkon Låstad Lygre, Anine Bernhoft Langeland, Brita Skodvin, Tormod Bjånes, Torgeir Storaas

Abstract

Background: Penicillin allergy is self-reported by 3-10% of patients admitted to hospital. The label is wrong in 90% of the cases and has severe health implications. Penicillin-delabeling can reverse the negative effects of the label, and pathways adapted to local practice are needed. No tools are available in Norway for penicillin delabeling outside an allergy clinic.

Objective: To create and validate the first penicillin delabeling pathway applicable outside an allergy clinic in Norway.

Methods: An interdisciplinary taskforce created a penicillin allergy delabeling program (PAD) adapted to the Norwegian health care system. This was validated in a prospective, single-center study. Very low-risk and low-risk patients underwent a direct oral penicillin challenge and high-risk patients were referred for allergologic evaluation.

Results: One-hundred forty-nine patients declaring penicillin allergy were included. Seventy-four (50%) were very-low- and low risk patients suitable for a direct oral penicillin challenge resulting in only 1 mild reaction. Sixty high-risk patients were eligible for an oral penicillin challenge after allergologic evaluation; 3 patients reacted non-severely.

Conclusion: We have created and demonstrated feasibility of the first penicillin delabeling program (PAD) applicable in a hospital setting outside an allergy clinic in Norway. Our data suggest this is safe and beneficial, with 49% patients delabeled through a direct oral penicillin challenge, performed without any serious adverse events, and an overall 87% delabeling rate.

Keywords: Critical pathway; Drug hypersensitivity; Penicillins.

© 2023 The Author(s).

Figures

Fig. 1
Fig. 1
Patient flow.

References

    1. Norwegian guidelines for the use of antibiotics .
    1. Steenvoorden L., Bjoernestad E.O., Kvesetmoen T.A., Gulsvik A.K. De-labelling penicillin allergy in acutely hospitalized patients: a pilot study. BMC Infect Dis. 2021;21(1):1083.
    1. Kimberly Md Mea Blumenthal. Recorded penicillin allergy and risk of mortality: a population-based matched cohort study. J Gen Intern Med. 2019;34(34):1685–1778.
    1. Stone C.A., Jr., Trubiano J., Coleman D.T., Rukasin C.R.F., Phillips E.J. The challenge of de-labeling penicillin allergy. Allergy. 2020;75(2):273–288.
    1. Fransson Sea The importance of prolonged provocation in drug allergy — results from a Danish allergy clinic. J Allergy Clin Immunol Pract. 2017;5(5):1394–1401.
    1. Robert R. Redfield M, Director. CDC. Core Elements of Hospital Antibiotic Stewardship Programs. In: Prevention CfDCa, editor. 1 ed 2019.
    1. EU Comission. EU Guidelines for the Prudent Use of Antimicrobials in Human Health. 2017.
    1. Gouvernement TN . 2015. National strategy against antibiotic resistance 2015-2020.
    1. Wurpts G., Aberer W., Dickel H., et al. Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics. Allergo Journal International. 2019;28(5):121–151.
    1. Collingridge D.S., Gantt E.E. The quality of qualitative research(.) Am J Med Qual. 2019;34(5):439–445.
    1. Collingridge D. Validating a Questionnaire Available from: ..
    1. Tsang S., Royse C.F., Terkawi A.S. Guidelines for developing, translating, and validating a questionnaire in perioperative and pain medicine. Saudi J Anaesth. 2017;11(Suppl 1):S80–S89.
    1. Delbecq A.L. A group process Model for problem identification and program planning. J Appl Behav Sci. 1971;7(4):466–492.
    1. Taylor E. We agree, don't we? The Delphi method for health environments research. Health Environments Research & Design Journal. 2020;13(1):11–23.
    1. Demoly P., Adkinson N.F., Brockow K., et al. International Consensus on drug allergy. Allergy. 2014;69(4):420–437.
    1. Romano A., Atanaskovic-Markovic M., Barbaud A., et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy. 2020;75(6):1300–1315.
    1. Dona I., Torres M.J., Montanez M.I., Fernandez T.D. In vitro diagnostic testing for antibiotic allergy. Allergy Asthma Immunol Res. 2017;9(4):288–298.
    1. Chua K.Y.L., Vogrin S., Bury S., et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. Clin Infect Dis. 2021;73(3):487–496.
    1. Shenoy E.S., Macy E., Rowe T., Blumenthal K.G. Evaluation and management of penicillin allergy: a review. JAMA. 2019;321(2):188–199.
    1. chiriac A.M. Controversies in drug allergy: drug allergy pathways. J Allergy Clin Immunol Pract. 2019;7(1):46–60.
    1. David A., Khan M, a. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022;150(6):1333–1393.
    1. Garvey L.H., et al. Danish guidelines on antibiotic allergy. 2019.
    1. Jan S. Nurses as adverse drug reaction reporting advocates. Eur J Cardiovasc Nurs. 2022
    1. Van De Sijpe G., Gilissen L., Vandebotermet M., Peetermans W.E., Spriet I., Schrijvers R. 2022. Non-invasive Delabeling and Refining of Beta-Lactam Allergy Labels in Inpatients to Optimize Antimicrobial Stewardship. Allergy.
    1. Song Y.C., Nelson Z.J., Wankum M.A., Gens K.D. Effectiveness and feasibility of pharmacist-driven penicillin allergy de-labeling pilot program without skin testing or oral challenges. Pharmacy. 2021;9(3)
    1. Jani Y.H. Sustaining and spreading penicillin delabeling: a narrative review of the challenges for service delivery and patient safety. Br J Clin Pharmacol. 2020;83:548–559.
    1. Sara F. Inconsistencies in penicillin allergy labels in hospital and primary care after allergy investigation. Clin Exp Allergy. 2023;53(9):969–973.
    1. Powell N., Wilcock M., Roberts N., Sandoe J., Tonkin-Crine S. Focus group study exploring the issues and the solutions to incorrect penicillin allergy-labelled patients: an antibiotic stewardship patient safety initiative. Eur J Hosp Pharm. 2021;28(2):71–75.
    1. Devchand M. Pathways to improved antibiotic allergy and antimicrobal stewardship practice- the validation of a beta-lactam antibiotic allergy assesment tool. Joural of Allergy and clinical immunology Pract. 2019;7(3):1063–1065.
    1. McHugh M.L. Interrater reliability: the kappa statistic. Biochem Med. 2012;22(3):276–282.
    1. Norwegian national guideline for the use of antibiotics in Hospitals 2023 Available from: ..
    1. Stephanie Albin SA. Prevalence and Characteristics of Reported Penicillin Allergy in an Urban Outpatient Adult Population.
    1. Norwegian immigration statistics. ..
    1. Gilissen L. Prevalence of antibiotic allergy labels in a tertiary referral center in Belgium. J Allergy Clin Immunol Pract. 2021;11(6):2415–2425.
    1. Borch . vol. 98. 2006. The Prevalence of Suspected and Challenge-Verified Penicillin Allergy in University Hospital Population. (Basic and Clinical Pharmacology and Toxicology).
    1. al . VSMPe. Urticaria: The 1-1-1 criterion for optimized risk stratification in β-lactam allergy delabeling. J Allergy Clin Immunol Pract. 2021;9(10):3697-3704.
    1. Sara Fransson Hmm, Dmsc, Mogens Kappel Md, Dmsc, Janni Hjortlund Md, PhD, Lars K. Poulsen PhD, Dmsc, Ask D. Kvisselgaard, Lene H. Garvey Md, PhD. The importance of prolonged provocation in drug allergy — results from a Danish allergy clinic. J Allergy Clin Immunol Pract. 2017;5(5):1394-1401.
    1. Bittner A. Incidence of resensitization after tolerating penicillin treatment in penicillin-allergic patients. Allergy Asthma Proc. 2004;25(3):161–164.
    1. Dona I. Resensitization in suspected penicillin allergy. Allergy. 2022;78(1):214–224.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere